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Background and purpose: Intravital imaging provides invaluable readouts for clinical
diagnoses and therapies and shows great potential in the design of individualized drug
dosage regimes. Ts is a mammalian free cell membrane-penetrating peptide. This study
aimed to introduce a novel approach to the design of a cancer-selective peptide on
the basis of a membrane-penetrating peptide and to explore its potential as a carrier of
medical substances.
Experimental approach: Ts was linked with a αvβ3-binding peptide P1c to create a
hybrid referred to as PTS. The hybrid was labeled with an FITC or Cy5.5 as an imaging
indicator to evaluate its in vitro and in vivo bioactivity.
Key results: Hemolysis tests proved that in comparison with Ts, PTS caused similar
or even less leakage of human erythrocytes at concentrations of up to 1mmol/L. Flow
cytometry assay and confocal microscopy demonstrated the following. (1) P1c alone
could target and mostly halt at the cancer cell membrane. (2) Ts alone could not bind
to the membrane sufficiently. (3) P1c greatly enhanced the binding affinity of PTS with
MDA-MB-231 breast cancer cells that upregulated αvβ3. (4) Ts conferred PTS with the
ability to traverse a cell membrane and thus facilitate the transmembrane delivery of
imaging probes. In vivo near-infrared fluorescence (NIRF) imaging demonstrated that the
imaging probes were rapidly concentrated in a MDA-MB-231 tumor tissue within 1 h after
intravenous injection.
Conclusions and implications: PTS exhibited the capability of targeting specific
tumors and greatly facilitating the transmembrane delivery of imaging probes.
Keywords: hybrid peptide, integrin αvβ3, molecular probe, tumor, near-infrared fluorescence imaging
Abbreviations: NIRF, near-infrared fluorescence; CTGF, connective tissue growth factor; CPPs, cell penetrating peptides;
AMPs, antimicrobial peptides; CLSM, confocal laser scanning microscopy; CD, Circular dichroism.
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INTRODUCTION
Molecular imaging provides anatomical and
functional/molecular information that facilitates the in vivo
diagnosis and monitoring of cancer (Liu et al., 2010; Barile
et al., 2014). Existing imaging approaches consume hours or
even days, and the corresponding preparations are relatively
complicated (Conway et al., 2014; Yi et al., 2014). Fluorescence-
based imaging approaches have been highlighted in the last
decades, but their application remains constrained by the
difficulty involved in inducing excitation from the inside
and given an intense background. The emerging near-
infrared fluorescence (NIRF) imaging technique offers a
revolutionary solution to the aforementioned problems (Yi et al.,
2014).
Tumor-specific cell-surface receptors allow cancer-selective
targeting for tumor diagnosis and therapy (Teesalu et al.,
2013; Reissmann, 2014). In a previous study, we screened a
fragment peptide P1c from human connective tissue growth
factor (CTGF). P1c could specifically be bound to the human
integrin αvβ3. After being coupled with ultrasuperparamagnetic
iron oxide particles (USPIOs), P1c was successfully applied in
the magnetic resonance imaging (MRI) of a human primary liver
cancer BEL-7402 that upregulated αvβ3 expression (Wu et al.,
2011b).
The upregulation of integrin in tumors and neovasculature
allows the preferential targeting of peptides (Mathejczyk et al.,
2011; Cao et al., 2012). Cell-penetrating peptides (CPPs) are
known as promising carriers of fluorophores or poorly soluble
drugs for delivery across lipid membranes (Andreev et al.,
2007; Reissmann, 2014). However, anticancer CCPs feature
unfavorable potential for mammal cells. As an important
group of CCPs, antimicrobial peptides (AMPs) derived from
synthetic or natural proteins are generally cationic peptides and
regarded as nontoxic to mammal cells. They preferentially target
bacterial lipid bilayers because of their electrical interactions
with the oppositely charged components of bacterial membranes
(Reissmann, 2014). AMPs facilitate membrane intercalation and
transmembrane transportation through a holing mechanism at
TABLE 1 | The amino acid sequence and chemical composition of peptides and their conjugates.
Peptide AA
sequence
Purified by
HPLC
(purity>95%)
MW (kD) Conjugate compositiona Purified by
HPLC
(purity>95%)
MW (kD) Conjugate compositiona Purified by
HPLC
(purity>95%)
TS SKKPVPIIY
CNRRSG
KCQRM
Yes 2419.2 FITC-TS (FITC)1(TS)1 Yes 2921.2 TS-Cy5.5 (TS)1(Cy5.5)1 Yes
P1c CIRTPKISK
PIKFELSG
Yes 1916.3 FITC-P1c (FITC)1(P1c)1 Yes 2419.8 P1c-
Cy5.5
(P1c)1(Cy5.5)1 Yes
PTS GSKKPVPII
YCNRRSGKC
QRMGSIRTP
KISKPIKFE
LSG
Yes 4359.6 FITC-PTS (FITC)1(PTS)1 Yes 4861.7 PTS-
Cy5.5
(PTS)1(Cy5.5)1 Yes
aThe composition indicated the molecule formula of each conjugate, for example, (FITC)1 (TS)1meant the conjugate was consisted of one FITC conjugated with one TS molecule.
cytoplasmic membranes (Rousselle et al., 2000; Duchardt et al.,
2009). The holing/membrane penetration process is prompt and
is usually accomplished within several minutes (Rahnamaeian,
2011; Fan et al., 2013). Integrating CCPs with a drug delivery
feature could greatly facilitate the rapid accumulation of medical
substrates in cells. Ts, which is an AMP with an antiparallel
β-sheet constrained by disulfide bonds, shows selectivity on
bacterial cell membranes, but its cytotoxicity is limited for
mammalian cells (Fehlbaum et al., 1996; Wu et al., 2010,
2011a).
A hybrid system that constitutes a tumor-preferred peptide
and a nontoxic membrane-penetrating peptide shows great
potential for cancer-specific delivery. In the present study, a
hybrid PTS peptide consisting of Ts following at the N-terminal
of P1c was designed to combine the merits of P1c and Ts. The
in vivo and in vitro activities of this hybrid system were evaluated
via flow cytometry, confocal laser scanning microscopy, and
NIRF imaging.
MATERIALS AND METHODS
Materials and Reagents
Preparation of the Fluorescence Probe
The peptides and their conjugates were all obtained from
Scipeptide (Shanghai, China) as indicated in Table 1. The
peptides were synthesized with a solid-phase method using a
model 432A synthesizer (Applied Biosystems Inc., Foster City,
CA; Angiolillo et al., 2004). Cy5.5-NHS or FITC was dropped
into the PTS, P1c, or Ts solution containing 0.1 mol/L sodium
carbonate-sodium bicarbonate (pH 9.0) at an equal molar ratio.
After overnight stirring in the darkness at 4◦C, the reaction was
blocked by adding an ammonium chloride solution to achieve
a final concentration of 50mmol/L. The crude product was
purified with HPLC with a C18 Delta-Pak column (Waters,
Bedford, MA) using a 0–60% acetonitrile gradient in 0.05%
trifluoroacetic acid as the mobile phase. The elution containing
Cy5.5-PTS, Cy5.5-P1c, Cy5.5-Ts, FITC-PTS, FITC-P1c, or FITC-
Ts conjugates was lyophilized and stored at−20◦C.
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Circular Dichroism (CD) Spectroscopy
To confirm the secondary structure of PTS, P1c, and
Ts, CD measurement was performed with a Jasco-810
spectropolarimeter (JASCO, Tokyo, Japan) using a quartz
cell with a path length of 1mm at 25◦C. The peptides were
dissolved in 50% (v/v) trifluoroethanol (TFE) at 200µmol/L for
all the measurements.
Hemolysis Assay
Human erythrocytes from a healthy adult were washed thrice
with an isotonic PBS buffer (pH 7.4) and then re-suspended
in four times the volume of the PBS before usage. Different
concentrations of PTS, P1c, or Ts were then added and
thoroughly mixed. Sterile PBS and 0.2% Triton X-100 were used
as negative and positive controls, respectively. After incubation
at 37◦C for 15min, the mixture was centrifuged at 10,000×
g for 1min. The supernatant was retrieved and measured for
OD350 with a spectrophotometer. The percentage of hemolysis
was calculated using the following equation: the percentage of
hemolysis (%) = (A−AB)/(AP−AB) × 100. A is the OD350
absorbance of a tested sample added with peptide, and AB is
the absorbance of a negative control without peptide addition,
whereas AP is the absorbance of a positive control added with
0.2% Triton X-100.
Flow Cytometry
Human Breast Cancer MDA-MB-231 cells or Human Embryonic
Kidney 293 cells were pre-cultured with and without 5µmol/L
free P1c peptide or 2mg/L anti-human αvβ3 monoclonal
antibody at 37◦C for 1 h. Afterward, the cells were harvested after
being rinsed thrice with PBS. FITC-PTS, FITC-P1c, or FITC-Ts
was then added to a final concentration of 2.5µmol/L followed by
an incubation of 30min at 37◦C in darkness before the conduct
of flow cytometry (Becton Dickinson, San Jose, CA, USA).
The expression of αvβ3 in the MDA-MB-231/HEK293 cells
was effectively evaluated via flow cytometry. The cells were briefly
incubated with a 2.5 mg/L anti-human αvβ3 integrin monoclonal
antibody in PBS with 1% FBS for 1 h at 4◦C. The cells were then
harvested and washed twice, followed by a 30min incubation
with 1 mg/L goat anti-mouse antibody-FITC at 4◦C. Finally, the
cells were carefully washed and fixed with 4% formaldehyde in
PBS before undergoing flow cytometry analysis. Amouse IgGwas
used as an isotype control.
Confocal Microscopy and Colorimetric Assay
MDA-MB-231/HEK293 cells were seeded and grown on a 35mm
cell culture dishes for 24 h. Thereafter, the cells were carefully
washed with PBS and then incubated with 2µmol/L of FITC-
P1c, FITC-PTS, or FITC-Ts for 30min in darkness. The cells
were then washed twice with PBS, fixed with 4% formaldehyde
in PBS, and finally examined with a confocal laser scanning
microscope (OLYMPUS-FV1000, Japan). Some cells were pre-
incubated with 4µmol/L free P1c peptide or 2 mg/L anti-human
αvβ3 monoclonal antibody before the addition of FITC-PTS to
determine the bioactivity of P1c moiety in PTS.
Tumor Xenografts Model
Animal experiments were performed according to a protocol
approved by the Animal Care and Use Committee of Southeast
University, China. Female BALB/C nude mice (4–6 weeks
old) were obtained from the Experimental Animal Center of
Yangzhou, China and reared in the Animal Environmental
Control Unit. Each nude mouse was subcutaneously inoculated
with approximately 5×106 MDA-MB-231 cells via the left foreleg.
When the tumors reached 0.4–0.6 cm in diameter (10–14 days
after implant), the mice were subjected to in vivo NIRF imaging
studies.
In vivo NIRF Imaging Study
Mice were anesthetized through an intraperitoneal injection
of pentobarbital sodium at a dosage of 30mg/kg. The
mice were weighted and grouped (n = 3) to ensure
that no considerable difference in weight appears between
groups. Primary experiments had determined that dosages
below 0.2 nmol/mouse resulted in weak signals, whereas those
above 5–25 nmol/mouse provided comparable signals. Therefore,
Cy5.5-PTS, Cy5.5-P1c, or Cy5.5-Ts at a dosage of 5 nmol/mouse
was administered via tail vein injection in this experiment.
The images at various time points were photographed with the
MaestroTM In-Vivo Imaging System (CRi, Woburn, MA, USA).
The orange filter (excitation, 586–631 nm; emission, 645 nm
longpass) was adopted. The tunable filter was automatically
stepped in 10 nm increments from 640 to 820 nm while the
camera captured images at each wavelength interval with a
constant exposure time period. The spectral fluorescence images
consisting of autofluorescence spectra and Cy5.5 spectra were
obtained and then analyzed on the basis of their spectral patterns
using the Maestro 2.10.0 software (CRi, Woburn, MA, USA). To
determine the tumor contrast, the mean fluorescence intensities
of the tumor (T) area at the left shoulder and the corresponding
normal tissue (N) area at the right shoulder were calculated.
H&E and Immunohistologic Staining
After NIRF imaging, the mice were sacrificed, and the
subcutaneous tumor tissues were completely removed before
being fixed with glutaraldehyde at 4◦C overnight, followed by
paraffin embedding and slicing into sections of 4µm. For H&E
staining, the sliced sections were dewaxed with xylene and
washed successively with ethanol and water. After hematoxylin
staining for 5min, the sections were washed with distilled
water, differentiated with ethanol for 30 s, soaked for 5min
in 50◦C water, and then counterstained in an eosin solution
for 2min. In the immunohistologic staining, the sections were
kept in a microwave oven at 92–98◦C for 15min for antigen
retrieval and then incubated with a 10% normal goat serum.
The sections were then incubated with 4 mg/L anti-human αvβ3
monoclonal antibody and then with a horseradish peroxidase
(HRP)-conjugated goat anti-mouse IgG (1:5000).
Data Processing and Statistics
All results were expressed as mean ± standard deviation (SD).
One-way analysis of variance and student’s t-test were performed
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to compare the differences between groups. Values of P < 0.05
were regarded as statistically significant.
RESULTS
CD Analysis of Peptide Structure
The CD spectrum indicated the secondary structure of the
peptides, and the results are shown in Figure 1, Table 2. PTS
and Ts were prone to adopt a β-sheet structure in TFE/H2O
buffer (1:1, v/v), whereas P1c did not exhibit a 2D structure.
PTS featured a∼40% β-sheet corresponding to∼15 amino acids,
similar to Ts that featured a ∼60% β-sheet corresponding to 12
amino acids.
Hemolysis Toxicity Assay
Figure 2 shows that Ts, P1c, and their hybrid exhibited similar
hemolytic activities at the same molar concentrations (P > 0.05).
In all the tested groups, hemolysis was <15% at concentrations
of up to 1mmol/L. This result indicated that the peptides were
relatively safe when applied in vivo. In addition, Ts maintained
its bioactivity without an increase in cytotoxicity after being
conjugated with P1c.
Fluorescent Probes Binding to
MDA-MB-231 Cells
As shown in Figure 3, the flow cytometry analysis revealed that
MDA-MB-231 cells were positively expressing αvβ3 (Figure 3A,
anti-αvβ3 MAb group) and that the signal of cells stained with
FITC-PTS or FITC-P1c was significantly improved compared
with that of the PBS control group or Ts group (P < 0.05,
Figures 3A,B, Figure S1). The staining signal was significantly
blocked by the addition of free P1c or anti-human αvβ3
monoclonal antibody (P < 0.05, Figures 3A,B, Figure S1).
As shown in Figure 4, no fluorescence appeared inside
the cytoplasma, but only the cell membrane exhibited strong
fluorescence after receiving FITC-P1c. By contrast, FITC-
PTS was capable of transmembrane translocation and equal
distribution in all the cells. This transmembrane delivery could
also be prohibited by blocking αvβ3, which was upregulated at
the cancer surface. Fluorescence intensity markedly decreased
when the cells were pretreated with P1c peptide or anti-αvβ3
monoclonal. P1c and anti-αvβ3 monoclonal antibody could
compete with FITC-P1c and FITC-PTS for αvβ3 docking sites.
HEK293 cells with little αvβ3 expression (Figure 3A, HEK293
anti-αvβ3 MAb group) were much less attractive for FITC-PTS
and -P1c probes (Figure 3C, Figures S2, S4).
HEK293 cells were used as a control and αvβ 3 was expressed
at low level below 1% in HEK293 cells. FITC-P1c and FITC-
PTS showed none affinity to HEK293 cells. In contrast to P1c
and PTS, Ts and its conjugates showed none affinity to both the
MDA-MB-231 and HEK293 cells.
TABLE 2 | The secondary structure of peptides by CD spectra.
Helix (%) Beta (%) Turn (%) Random (%) Total (%)
PTS 0 40.5 5.9 53.6 100
P1c 0 0 8.3 91.7 100
Ts 0 60.8 5.1 34.1 100
FIGURE 2 | Hemolytic toxicity of PTS, P1c, and Ts. Human erythrocytes
were incubated in phosphate buffer with various concentrations of peptides at
37◦C for 15min. There was no significant difference between three groups at
tested concentrations (P > 0.05).
FIGURE 1 | The CD spectra of the peptides in TFE/H2O buffer (1:1, v/v).
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FIGURE 3 | Interaction between fluorescent probes with cells by flow cytometry. (A) The MDA-MB-231 cells were treated with PBS, anti-αvβ3 monoclonal
antibody followed by goat anti-mouse antibody-FITC, a mouse IgG followed by goat anti-mouse antibody-FITC, FITC-PTS, FITC-P1c, FITC-Ts, free P1c peptide
followed by FITC-PTS, anti-αvβ3 monoclonal antibody followed by FITC-PTS, separately (n = 3), and the HEK293 cells were treated with anti-αvβ3 monoclonal
antibody followed by goat anti-mouse antibody-FITC. (B) The fluorescent intensity of the MDA-MB-231 cells after receiving PBS or fluorescent probes. (C) The
fluorescent intensity of the MDA-MB-231 cells and HEK231 cells after receiving FITC-PTS, -P1c, and -Ts. *P < 0.05 compared to FITC-PTS group. #P < 0.05
compared to each other.
In vivo Fluorescence Imaging
Figure 5A shows typical NIRF images of nude mice
bearing subcutaneous MDA-MB-231 breast tumor after an
intravenous injection of 5 nmol Cy5.5-PTS. Each animal
became fluorescent after injection, and the subcutaneous
MDA-MB-231 tumor could be clearly delineated from the
surrounding background tissue from 1 to 24 h. The tumor
uptake reached its maximum at 8 h (Figures 5A, 6A left)
and slowly washed out over time. By contrast, normal tissue,
except liver tissue, showed a rapid uptake and relatively fast
clearance. The ex vivo evaluation of the excised organs at 8 h
post-injection of Cy5.5-PTS demonstrated that the compound
was predominantly uptaken by the MDA-MB-231 tumor
(Figures 5B,C).
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FIGURE 4 | Cellular localization of fluorescent probes. The merged view of laser confocal florescence microscopy of MDA-MB-231 or HEK293 cells treated for
30min with FITC-PTS, FITC-P1c, FITC-Ts, free P1c peptide followed by FITC-PTS, and anti-αvβ3 monoclonal antibody followed by FITC-PTS, separately.
The Cy5.5-P1c probe also certainly showed potential
for tumor imaging (Figure 6A middle). However, the
tumor-to-normal tissue contrast ratios were significantly
smaller than those of Cy5.5-PTS at time points from 1 to 24 h
(P < 0.05; Figure 6B). In addition, a slight tumor-to-normal
tissue contrast was observed in the Cy5.5-Ts group (Figure 6A,
right), although the tumor-to-normal tissue contrast ratios were
much smaller than those of the Cy5.5-PTS group and Cy5.5-P1c
group (Figure 6B).
Histologic Evaluation
The HE staining of tumor tissue showed that the tumor cells
exhibited pleomorphism and nucleus hyperchromasia. Mitotic
phases and irregularly appearing nuclei were also observed
(Figure 7A). The immunohistological staining of tumor tissues
demonstrated that αvβ3 was expressed in the MDA-MB-231
tumor cells (Figure 7B).
DISCUSSION
Cell membrane-penetrating peptides employ a unique
mechanism to rupture cellular membranes. Their sequence
composition and charge aspects define their targeting specificity
over different cellular types. Modifying their activity on the
basis of sequences is extremely difficult. A single amino acid
substitution or insertion would even overturn their bioactivities.
In the present study, Ts was used as an example to show how
to purposively design a novel peptide with distinctive activity
on the basis of AMPs. The CCPs might once again become an
important resource for anticancer substrates.
On the basis of our previous findings, we designed and
synthesized a hybrid peptide (PTS) comprising the integrin αvβ3-
binding peptide P1c linked to the C-terminal of the antimicrobial
peptide (AMP) Ts. We used bacterial-preferred AMP peptides
instead of anticancer CCPs because unlike anticancer CCPs, Ts
would not result into an unfavorable cytotoxicity on normal cells.
The anticancer CCPs showed promising anticancer activity, but
their cytotoxicity was extremely high because of their surfactant
resembling mechanism of action (Yeaman and Yount, 2003).
AMPs were considered nontoxic to mammal cells but could not
target cancer cells sufficiently. Therefore, we designed a hybrid by
adding an extra αvβ3-binding peptide P1c to Ts.
This design could be extended to other combinations of
tumor-targeting peptides with mammalian-cell-free CCPs.
The activities of CCPs are 2D-structure dependent (Fehlbaum
et al., 1996; Nguyen et al., 2011). So the combined tumor-
targeting peptides should be as simple/short as possible and
not affect the structure of the CCPs. A flexible linker of
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FIGURE 5 | In vivo NIRF imaging. The average signal counts were quantified for each sample/area and plotted into different colors. (A) Typical NIRF images of
nude mice bearing subcutaneous MDA-MB-231 breast tumor after intravenous injection of Cy5.5-PTS from 0 to 24 h. (B) NIRF images of dissected organs from
model animal at 8 h after intravenous injection of Cy5.5-PTS (left, bright field; right, NIRF imaging) and (C) the average scaled counts of dissected tissues. The tumors,
major tissues, and organs were dissected 8 h post-injection for imaging. 1, skin; 2, muscle; 3, bone; 4, lung; 5, heart; 6, kidney; 7, liver; 8, spleen; 9, tumor. This
experiment was repeated for three times with 2∼3 mice for each time. *P < 0.05 compared to tumor tissue.
two amino acids was usually added between the moieties.
There are numerous peptides reported of potential to target
tumor-associated receptors, tissues or pathways (Raha
et al., 2011), such as RGD targeting integrin (Ruoslahti and
Pierschbacher, 1986), CDX-110 under developing by Celldex
Therapeutics targeting EGFR (Del Vecchio and Wong, 2010),
IPLVVPL targeting prostate cancer Hepsin (Kelly et al.,
2008), and CREKA targeting tumor stroma (Simberg et al.,
2007).
CD spectrum confirmed that PTS possessed a secondary β-
sheet similar to Ts. Hemolysis assay demonstrated that PTS,
Ts, and P1c exhibited similar but limited hemolysis toxicity at
concentrations of up to 1mmol/L. This result implied that Ts
maintained its function in the hybrid and helped PTS to pore on
the membrane.
The flow cytometry and confocal microscopy results revealed
that FITC-labeled PTS or P1c could sufficiently target the MDA-
MB-231 cancer cells. The inhibitory effect of P1c peptide or
anti-αvβ3 monoclonal antibody indicated that the targeting of
FITC-PTS and FITC-P1c toward cancer cells was triggered by
an initial interaction between P1c with αvβ3 located on the cell
surface. HEK293 or MCF-7 cells (Figures S3, S4) lacking αvβ3
were much less attractive for P1c or PTS peptide. FITC-PTS
could penetrate the cell membrane, thereby suggesting that Ts
caused its hybrid capability of membrane penetration. The FITC-
Ts group and the control group did not show any differences. This
outcome indicated the poor membrane binding capability of Ts
for MDA-MB-231 cancer cells. Overall, the results matched the
speculation of the present study. The transmembrane delivery of
PTS involved three steps. (1) The initial targeting of PTS onto the
MDA-MB-231 cell membrane was achieved by the P1c peptide,
which could be specially bound to αvβ3 that was highly expressed
on the cell membrane of MDA-MB-231. (2) After the initial
binding, the Ts peptide was brought to the surface of the lipid
bilayer and then intercalated into the membrane after adopting a
special β-sheet structure. (3) The membrane then became leaky
and allowed the entrance of signal probes (Figure 8).
After being concentrated onto the surface of the cytoplasma
membrane, PTS was rapidly translocated inside the cytoplasma
within 30min. This effect is significantly different from the
conventional receptor mediated endocytosis, which generally
takes a much longer course. A considerable number of research
suggests that AMPs could rapidly intercalate the lipid membrane
and make it leaky within 10min (Yeaman and Yount, 2003).
Thus, the rapid translocation across the cell membrane implies
that PTS employed a mechanism similar to that of TS to
penetrate the cell membrane. Such mechanism is one of the main
advantages of this design.
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FIGURE 6 | In vivo NIRF imaging. (A) Representative NIRF images obtained
from model animals at 8 h after intravenous injection of Cy5.5-PTS (left),
Cy5.5-P1c (middle) and Cy5.5-Ts (right), respectively. (B) Tumor-to-normal
tissue contrast ratios of three NIRF probes at time points. *P < 0.05 vs.
Cy5.5-P1c group. #P < 0.05 vs. Cy5.5-Ts group.
The in vivo effect of PTS was further evaluated by applying it
for in vivo imaging. NIRF imaging, as a complement to nuclear
imaging methods, is a powerful tool for introvital imaging in
preclinical models (Yi et al., 2014). It provides both anatomical
and functional/molecular information by using exogenous
fluorescent probes (Yi et al., 2014). Cy5.5 is broadly used in NIRF
imaging studies because of its different characteristics, including
its relative bulkiness, small Stokes shift, low signal loss, and strong
anti-jamming capability (Licha et al., 2000; Hsu et al., 2006). The
PTS peptide was conjugated with Cy5.5 and applied for real-time
NIRF imaging.
The in vivo NIRF imaging studies showed that the
MDA-MB-231 tumors were clearly visible with high contrast
to the contralateral background at all measured time points
(1–24 h) after the Cy5.5-PTS injection. Moreover, the tumor-to-
normal tissue contrast ratios reached their maximum at 8 h post-
injection. The probe exhibited fast tumor targeting (as early as 1 h
post-injection) and markedly slower washout in tumors than in
normal tissues. These results supported the preferential homing
of Cy5.5-PTS to tumors and/or tumor neovasculature and its
rapid accumulation in tumor tissue. Consistent with the imaging
findings in vivo and ex vivo, the immunohistological examination
revealed the positive expression of integrin αvβ3 in the tumor
cells. In addition, the accumulation of the Cy5.5-PTS probe was
positively correlated with the expression and distribution density
of αvβ3 in the tumor site, Cy5.5-P1c resulted in considerably
FIGURE 7 | Histologic evaluation of MDA-MB-231 tumor xenograft.
(A) H&E staining. (B) Immunohistologic staining of tumor tissues illustrated
αvβ3-positive expression of tumor cells using anti-αvβ3 monoclonal antibody.
smaller contrast ratios compared with Cy5.5-PTS. This difference
was consistent with the results from the confocal microscopy,
which indicated that P1c could only localize the probes at the
cell membrane and that Ts would help PTS penetrate into the
cytoplasm and accumulate in the tumor tissue in significantly
high concentrations. The immunohistological staining had been
repeated for three times but not in consistent with the FACS
results. The average ratio of the cells expressing αvβ3 was between
20 and 30%. It might be possible that the cells altered their
expression profile after implanted into the mice. This required
further exploration.
Some cyanine dyes, such as Cy5.5, have been reported to
be capable of tumor accumulation without conjugation with
a specific targeting molecule (Licha et al., 2000). The NIRF
probes in this study might have degraded because of the dye
molecules that non-specifically accumulated in the tumor. This
condition may partially explain the slight tumor imaging found
in the Cy5.5-Ts group. The Cy5.5-Ts and -P1c groups also served
as controls, and the merit of using PTS is undeniable when
comparing its effect with that of Cy5.5-Ts or -P1c. In addition,
we observed a relatively higher accumulation of PTS-Cy5.5 in the
liver than in other organs, which suggested hepatic elimination as
the major mechanism of PTS degradation.
This study has certain limitations. First, the subcellular
location of the FITC-labeled probes was investigated for 30min
only; hence, a longer investigation is needed. Second, the in vivo
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FIGURE 8 | Schematic diagram of fluorescent probes acting on MDA-MB-231 cell membrane. (A) FITC-PTS firstly binds to integrin αvβ3 of tumor cell, and
β-sheet structure tightly attaches on membrane, then FITC-labeled hydrophobic head inserts into phospholipid bilayer and rapidly penetrates into the cell.
(B) FITC-P1c combines with integrin αvβ3 on tumor cell. (C) FITC-Ts has no effect on the cell membrane.
experimental data were obtained from a small number of animals
(three mice for each group). Moreover, the follow-up observation
was only limited to 24 h; hence, the long-term effect of the probe
is still unknown. Third, the exact mechanism for PTS penetrating
cells needs further studies.
PTS might be useful for drug delivery, but this design of
PTS-dye is more suitable for imaging. How to combine the drug
with PTS is much more complicated. Only drugs with functional
groups could be linked to the peptide through chemical method.
If we use a design like PTS-liposome, the transmembrane
mechanism should bemuch different from PTS alone. So we used
cy5.5 and FITC which could easily link with PTS for imaging
application.
In conclusion, we designed a hybrid peptide (PTS) comprising
P1c and Ts. P1c led the binding of PTS to the MDA-
MB-231 cancer cell membrane, and Ts facilitated the rapid
translocation of PTS across the cell membrane. PTS exhibited
good specificity in the MDA-MB-231 tumor imaging via NIRF
and showed great potential as a carrier in special tumor
imaging.
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